GKOS Stock Glaukos Corporation
Today’s call · GKOS
All live ideas →4 of 6 technical checks lean bullish
GKOS is in an uptrend, momentum soft. $247.16 is the level overhead; $225 the first support below.
- A close above $247.16 on rising volume (breakout).
- A pullback to $225 that holds (entry near support).
The brief
All readings
Levels that matter
Compare with…
Glaukos (GKOS) stock analysis, November 20, 2026: Strong bullish case on short‑term upside
Glaukos (GKOS) closed at $237.69 on November 20, 2026, after slipping 0.17% on the day but still sitting well above its 40‑week average and the 225‑round support that underpins the current structure. The daily trend follows the weekly uptrend, and the stock has outperformed the S&P 500 by 36.6% over the past 50 days and XLV by 24.5% over the same span. The balance of evidence points to a bullish outlook for the next two to six weeks, with high conviction despite a modest reward‑to‑risk profile.
Why it matters
The recent price action reflects a market that has already priced in the long‑term uptrend, as the stock remains above both its 50‑day ($190.96) and 200‑day ($150.33) simple moving averages and the 40‑week average. The daily close of $237.69 is still 3.8% below the 52‑week high of $247.16, indicating room for upside if buying pressure resumes. Volume on the last session was 55.5% below the 20‑day average, suggesting limited participation and leaving the door open for a volume‑driven breakout.
Relative performance metrics reinforce the stock’s strength. Over the past 50 days GKOS has outpaced the S&P 500 by 36.6% and the healthcare sector ETF XLV by 24.5%, while its 5‑day decline of 3.27% was modest compared with the market’s 8.7% drop and XLV’s 6.29% slide. The stock’s outperformance is therefore not merely a market‑wide rally but a specific advantage relative to its peers.
Analyst sentiment is broadly positive, with 13 analysts assigning a consensus of strong buy and an average price target of $243.85, only 2.5% below the current price. The target range spans $225 to $270, framing the current price near the lower end of the consensus band but still within the analysts’ expectations. Valuation therefore does not appear stretched, and the modest discount to the mean target adds a supportive nuance to the bullish case.
There is no current news catalyst driving the move; the news feed is empty, indicating that the price action is driven by technical factors and the broader market environment rather than a specific corporate event.
What the evidence says
The long‑term thesis remains intact. GKOS sits above its 40‑week average, its 50‑day SMA, and the 225‑round support that defines the current structural base. The RSI at 61.4 signals that the stock is not overbought, and the ATR of $12.25 provides a reasonable volatility gauge for stop placement. The weekly trend is upward, and the daily trend is aligned with that weekly bias, confirming that the stock is still in the growth phase of its longer cycle.
For the next two to six weeks the balance of evidence leans positive with high conviction. The assessment cites three of four conviction points: the daily trend’s alignment with the weekly uptrend, a 36.6% outperformance versus the S&P 500 over 50 days, and a 24.5% outperformance versus XLV over the same period. The strongest counter‑argument is the low volume on recent sessions—55.5% below the 20‑day average—which could limit the immediacy of a breakout. However, this volume weakness does not overturn the bullish bias because the structural support at $225 remains intact and the price is still well above the trend‑ending level of $184.68.
Levels that matter
The structure holds above the $225 round level, which also serves as the first crack point in the assessment. A break below $225 would signal the first structural breach, while a close under $184.68—a swing‑zone level—would mark the end of the current uptrend according to the picture‑change rule.
The breakout math targets a daily close above $247.16, the 52‑week high, on volume exceeding the 20‑day average. If that occurs, the first target is $250, a round level with a reward‑to‑risk of 0.1 based on the $221.94 stop. The next target is $275, also round, offering a reward‑to‑risk of 1.1. The math does not achieve a 3‑to‑1 reward‑to‑risk ratio; a price of roughly $280 would be needed to reach that threshold, which lies beyond the current target set.
What would change the picture
A weekly close below $184.68, the swing‑zone level that defines the trend‑ending zone, would alter the outlook dramatically, indicating that the uptrend has been exhausted. The only non‑price factor that could shift the narrative is a material earnings surprise—either a significant miss or beat—given the proximity of the next earnings report on October 28, 2026.
What to watch
- October 28, 2026 earnings release; the earnings per share figure will be the key number.
- Sector developments in healthcare devices that could affect XLV, such as FDA approvals or regulatory changes.
- Analyst revisions and any movement in the consensus price target range, especially if the mean target moves above the current price.